11. Inoue K, Masuda N, Iwata H, Takahashi M, Ito Y, Miyoshi Y, et al. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer. 2021;28:1038-50. This evidence concerns the gene ERBB2 and breast carcinoma.